Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chuanzhitongluojiaonang for acute ischemic stroke (Phase 4, randomized, double-blind, placebo-controlled)
ChiCTR2300074147Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2023
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ischemic stroke comparing Chuanzhitongluojiaonang + conventional western medicine with Placebo + conventional western medicine (2 arms). Primary endpoints: Rate of 90-day modified Rankin Scale (mRS) score 0–1, Mortality at 90 days and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
chuanzhitongluojiaonang
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300074147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074147.